← Leaderboards
Nicholas Lachlan Opie
Carnegie-Mellon University
$1,571,756
Attributed
$6,287,022
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2021–23$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
Funding mix
By agency
NIH$6,287,022 · 2
By mechanism
UH3$4,230,113 · 1
UG3$2,056,909 · 1
Top collaborators
- Thomas J Oxley3 shared
- David Francis Putrino3 shared
- Douglas J Weber3 shared
Most similar at Carnegie-Mellon University
Same institution · by research overlap
- Thomas J Oxley$2,071,259
- David Francis Putrino$2,071,259
- Eni Halilaj$2,179,833
- Yoed Rabin$7,300,759
- Vladimir Cherkassky$209,512
Others in their field
Other Emerging Leaders on “Adverse Event”
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$26,732,375
- Barbara Halina Braffett · George Washington University$18,816,779
- Ionut Bebu · George Washington University$18,816,779
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
Research focus
Adverse EventAffectAmyotrophic Lateral SclerosisAdverse Event MonitoringAnimalsAnimal TestingAreaAttentionAustraliaAnimal ModelBlood VesselsBrainBrain Computer InterfaceBrain ImagingCaregiver BurdenCaregiversCathetersCerebrovascular SystemCessation Of LifeChronicClinical EfficacyClinical TrialsCommercializationCommunication
Grant awards (3)
SWITCH Trial: Early Feasibility Study of Stentrode BCI for Augmentative Communication$1,970,860
UH3 · FY2023 · NS
SWITCH Trial: Early Feasibility Study of Stentrode BCI for Augmentative Communication$2,259,253
UH3 · FY2022 · NS
SWITCH trial: Early feasibility study of Stentrode BCI for augmentative communication$2,056,909
UG3 · FY2021 · NS